Return to search results
Abrocitinib
Cibinqo (abrocitinib) is an oral prescription medication manufactured by Pfizer, classified as a Janus Kinase inhibitor. It's used to treat moderate-to-severe atopic dermatitis (eczema) in adults and adolescents. Available in tablet form with strengths of 50mg, 100mg, and 200mg. This information was generated using AI and is provided for informational and research purposes only.
Complete Metadata
| @type | dcat:Dataset |
|---|---|
| accessLevel | public |
| accrualPeriodicity | R/P1Y |
| bureauCode |
[
"009:10"
]
|
| contactPoint |
{
"fn": "Division of Drug Information",
"@type": "vcard:Contact",
"hasEmail": "mailto:druginfo@fda.hhs.gov"
}
|
| description | Cibinqo (abrocitinib) is an oral prescription medication manufactured by Pfizer, classified as a Janus Kinase inhibitor. It's used to treat moderate-to-severe atopic dermatitis (eczema) in adults and adolescents. Available in tablet form with strengths of 50mg, 100mg, and 200mg. This information was generated using AI and is provided for informational and research purposes only. |
| distribution |
[
{
"@type": "dcat:Distribution",
"title": "Abrocitinib",
"mediaType": "text/html",
"description": "
Access the FDA dataset for Abrocitinib — ANDA 213871 submitted by Mylan Institutional LLC
",
"downloadURL": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=213871"
}
]
|
| identifier | ANDA213871 |
| issued | 2016-09-16 |
| keyword |
[
"drug",
"fda",
"health-care",
"medications",
"public-health"
]
|
| landingPage | https://www.fda.gov/drugs |
| license | https://open.fda.gov/license |
| modified | 2025-03-17 |
| programCode |
[
"009:002"
]
|
| publisher |
{
"name": "U.S. Food and Drug Administration",
"@type": "org:Organization"
}
|
| theme |
[
"FDA"
]
|
| title | Abrocitinib |
